KiOmed Pharma

KiOmed Pharma is a private, Belgium-based biotechnology company capitalizing on over a decade of research into its exclusive KiOmedine® CM-chitosan platform. Derived from the white button mushroom, this pharma-grade, bioresorbable biopolymer forms the core of its pipeline targeting osteoarthritis (via a fluid implant), dermal fillers for skin aging, and formulations for ophthalmology. The company is in the commercial stage for its osteoarthritis product, KiOmedine vs one, and operates with an ISO 13485-certified manufacturing process, positioning it as a developer of differentiated medical devices in large, underserved markets.

KiOmedine® CM-chitosan, a patented, animal-free, medical-grade carboxymethyl chitosan biopolymer derived from the white button mushroom. It features unique lubrication, antioxidant (free radical scavenging), and hydrating properties, suitable for injectable and implantable medical devices.

In osteoarthritis, KiOmedine vs one competes directly with hyaluronic acid-based viscosupplements and other intra-articular therapies. In dermatology, it enters a crowded dermal filler market dominated by companies like Allergan (Juvéderm) and Galderma. In ophthalmology, it would compete with numerous artificial tear and dry eye formulations. Its key competitive edge is its unique biomaterial with combined lubricating, protective, and hydrating properties.